# A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs in Adults With Hepatitis C Virus Infection, Who Are Either Treatment-naive or Treatment-experienced in Brazil

> **NCT02442271** · PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 222 (actual)

## Conditions studied

- Chronic Hepatitis C Infection

## Interventions

- **DRUG:** ombitasvir/paritaprevir/ritonavir and dasabuvir
- **DRUG:** ribavirin

## Key facts

- **NCT ID:** NCT02442271
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04-27
- **Primary completion:** 2016-07-04
- **Final completion:** 2016-09-26
- **Target enrollment:** 222 (ACTUAL)
- **Last updated:** 2017-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02442271

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02442271, "A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs in Adults With Hepatitis C Virus Infection, Who Are Either Treatment-naive or Treatment-experienced in Brazil". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02442271. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*